Mitoxantrone Baxter Special Precautions

Myelosuppression or Other Severe Infections: A complete blood count must be checked before each administration of mitoxantrone, as well as at least once during each treatment cycle (see Adverse Reactions).
Mitoxantrone should be administered with caution to patients suffering from myelosuppression and/or pancytopenia or severe infections.
Renal Impairment: Use with caution in patients with severe renal impairment.
Hepatic Impairment: Use with caution in patients with severe hepatic impairment.
Liver function parameters must be checked before each administration of mitoxantrone, as well as at least once during each treatment cycle (see Adverse Reactions).
Dose reduction may be required, dependent on liver function parameters (i.e., bilirubin).
Effects on ability to drive and use machines: No information on the effects of mitoxantrone on the ability to operate an automobile or other heavy machinery.
Use in Children: There have been no studies performed by Baxter Healthcare Corporation in the pediatric population.
Use in the Elderly: In geriatric patients, monitoring for toxicities and the need for dose adjustment should reflect the higher frequency of decreased hepatic, renal, cardiac, or other organ function, and concomitant diseases or other drug therapy in this population.